Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Justin D. Westenberg"'
Autor:
Martine F Thijs-Visser, Mijntje B. Vastbinder, Liesbeth E. M. Struik, Hanneke J. M. Zuetenhorst, Justin D. Westenberg, C. Louwrens Braal, Koen M. W. T. Lommen, Ron H.J. Mathijssen, Robbert J. van Alphen, Stijn L.W. Koolen, Agnes Jager, Esther Oomen-de Hoop, Peter de Bruijn, Quirine C. van Rossum-Schornagel
Publikováno v:
Clinical Pharmacokinetics, 61(4), 527-537. Adis
Background: Endoxifen is the most important active metabolite of tamoxifen. Several retrospective studies have suggested a minimal or threshold endoxifen systemic concentration of 14–16 nM is required for a lower recurrence rate. The aim of this st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2284dea60a5044e1d335b11be933342
https://pure.eur.nl/en/publications/b67beed5-f844-4074-a150-898c7b3e6de5
https://pure.eur.nl/en/publications/b67beed5-f844-4074-a150-898c7b3e6de5
Autor:
C. Louwrens Braal, Justin D. Westenberg, Sanne M. Buijs, Steven Abrams, Tessa A. M. Mulder, Ron H. N. van Schaik, Stijn L. W. Koolen, Agnes Jager, Ron H. J. Mathijssen
Publikováno v:
Breast cancer research and treatment
Breast Cancer Research and Treatment, 195(1):195, 65-74. Springer New York
Breast Cancer Research and Treatment, 195(1):195, 65-74. Springer New York
Introduction Endoxifen—the principal metabolite of tamoxifen—is subject to a high inter-individual variability in serum concentration. Numerous attempts have been made to explain this, but thus far only with limited success. By applying predictiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b1ec86ba8b860d344d13b1ebcc6226
http://hdl.handle.net/1942/37900
http://hdl.handle.net/1942/37900
Autor:
C Louwrens, Braal, Agnes, Jager, Esther Oomen-de, Hoop, Justin D, Westenberg, Koen M W T, Lommen, Peter, de Bruijn, Mijntje B, Vastbinder, Quirine C, van Rossum-Schornagel, Martine F, Thijs-Visser, Robbert J, van Alphen, Liesbeth E M, Struik, Hanneke J M, Zuetenhorst, Ron H J, Mathijssen, Stijn L W, Koolen
Publikováno v:
Clinical pharmacokinetics. 61(4)
Endoxifen is the most important active metabolite of tamoxifen. Several retrospective studies have suggested a minimal or threshold endoxifen systemic concentration of 14-16 nM is required for a lower recurrence rate. The aim of this study was to inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cc5759601dbbcfda1b6f119837d89c71
https://pubmed.ncbi.nlm.nih.gov/34786650
https://pubmed.ncbi.nlm.nih.gov/34786650
Autor:
C. Louwrens Braal, Justin D. Westenberg, Sanne M. Buijs, Steven Abrams, Tessa Mulder, Ron van Schaik, Stijn Koolen, Agnes Jager, Ron Mathijssen
Introduction: Endoxifen – the principal metabolite of tamoxifen – is subject to a high inter-individual variability in serum concentration. Numerous attempts have been made to explain this, but thus far only with limited success. By applying pred
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b183864462e0ca251b3b5fc12f0f6fb
https://doi.org/10.21203/rs.3.rs-689481/v1
https://doi.org/10.21203/rs.3.rs-689481/v1